GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt flag Egypt · Delayed Price · Currency is EGP
453.00
-9.00 (-1.95%)
At close: Aug 25, 2026

GlaxoSmithKline S.A.E Cash Flow Statement

Millions EGP. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
192.06213.23173.9860.46735.38154.64
Depreciation & Amortization
67.3861.4752.9247.7949.8157.19
Loss (Gain) From Sale of Assets
-0.61-0.482.4-0.17-5.94-0.24
Asset Writedown & Restructuring Costs
5.47--137.65101-
Loss (Gain) on Equity Investments
-18.4-35.3-118.12-12.159.21
Provision & Write-off of Bad Debts
-46.55-5.3264.64-18.6611.0130.79
Other Operating Activities
375.02230.83386.5224.11-530.2689.78
Change in Accounts Receivable
159.65-142.62-333.87-366.5-231.15-18.53
Change in Inventory
-98.73-649.32-420.25-263.59-47.2-42.95
Change in Accounts Payable
144.15142.0964.9156.24-322.3245.45
Change in Other Net Operating Assets
-1,814426.25-394.38506.84-82.97-133.15
Operating Cash Flow
-1,035240.83-404.15302.271,036192.19
Operating Cash Flow Growth
----70.82%439.06%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-267.64-177.28-124.34-77.08-48.76-35.76
Sale of Property, Plant & Equipment
0.610.61-5.426.990.61
Other Investing Activities
266.09292.05-101.72157.15-200-
Investing Cash Flow
-526.04115.39-226.0785.5-241.77-35.15

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt Issued
1,483-----
Short-Term Debt Repaid
-----118.21-27.52
Long-Term Debt Repaid
--43.06-43.38-28.98-19.21-24.11
Total Debt Repaid
-46.24-43.06-43.38-28.98-137.43-51.63
Net Debt Issued (Repaid)
1,437-43.06-43.38-28.98-137.43-51.63
Common Dividends Paid
-98.88-14.13-69.67-131.59-111.04-5.58
Other Financing Activities
111.07105.18-10.616.3-33.5-48.42
Financing Cash Flow
1,44948-123.66-144.28-281.97-105.63

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-111.88404.22-753.87243.49512.2951.41

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,30363.55-528.49225.2987.26156.43
Free Cash Flow Growth
----77.19%531.14%-
Free Cash Flow Margin
-36.00%1.70%-17.67%10.05%54.15%8.63%
Free Cash Flow Per Share
-15.600.76-6.332.7011.821.87
Levered Free Cash Flow
-1,252319.89-523.15178.77108.3749.65
Unlevered Free Cash Flow
-1,223327.15-516.53202.5129.3180.07

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
-3.3510.637.9633.548.67
Cash Income Tax Paid
-108.4248.27173.0410.7229.97
Change in Working Capital
-1,609-223.6-1,08432.99-683.64-149.18